Updated CKD Anemia Management Guidelines Released

A new clinical guideline on the management of anemia in chronic kidney disease (CKD) was published online on September 15 in the *Annals of Internal Medicine*. The update, developed by a panel of nephrology experts, revises earlier recommendations and provides evidence‑based guidance for clinicians treating CKD patients who develop anemia. It outlines optimal hemoglobin targets, the use of erythropoiesis‑stimulating agents (ESAs), and strategies for iron supplementation, while addressing safety concerns related to high ESA doses and cardiovascular risk.

Key changes include a more restrictive hemoglobin goal range of 10–12 g/dL for most CKD patients, a recommendation to prioritize iron repletion before initiating or escalating ESA therapy, and clearer criteria for when to switch between intravenous and oral iron formulations. The guideline also emphasizes individualized treatment plans based on patient comorbidities, dialysis status, and risk of adverse events. By integrating recent trial data and real‑world evidence, the update aims to improve patient outcomes and reduce complications associated with anemia management in CKD.

The publication of these revised recommendations underscores the ongoing effort to refine CKD care and highlights the importance of evidence‑driven practice. Clinicians are encouraged to review the full guideline to align their treatment protocols with the latest consensus, ultimately enhancing the quality of care for patients with CKD‑related anemia.